TORONTO, Oct. 30, 2013 /CNW/ - MediJean announced today it is developing strains of medical marijuana specifically for treating conditions affecting children and young adults. Through the company's research and development program, MediJean is experimenting with chemical compositions aimed at the reduction of pain and behavioural conditions that impact these individuals.
"There are many examples of medical marijuana helping to treat ailments in children and young adults," said Anton Mattadeen, chief strategy officer at MediJean. "Last month, I spoke at the Brain Injury Association of Canada conference. At the event, I met an amazing young man who was suffering from severe neuropathic pain caused by a brain injury. He told me the only thing that alleviated his condition without side effects was a certain strain of cannabis, which he has difficulty obtaining on a regular basis. We're committed to working with him and his doctor, to fix that problem and get him the medicine he needs."
MediJean understands that giving medical marijuana to a child or young adult is a big decision and a choice that parents, patients and doctors must make together.
"We are here to work with parents, patients and doctors to provide a solution that is safe, quality-assured and designed to provide the relief and therapeutic value the child or young adult needs," said Mattadeen. "Diseases and ailments don't discriminate because of age; decisions should be focused on ensuring a child is receiving the most effective, robust and best treatment possible."
As part of an intensive R&D program based on the most promising plant genetics worldwide, MediJean will be recommending more than 20 strains of medical marijuana for use by children and young adults. Each strain will be designed to reduce or eliminate the psychoactive effects of Tetrahydrocannabinol (THC), through the application of an elevated terpene structure, coupled with balanced levels of Cannabidiol (CBD) and THC.
MediJean is leading the rebirth of medical marijuana through a laser focus on research, quality and patient experience by implementing best practices here and around the world. Doctors and nurse practitioners will understand and safely prescribe it within a clinical framework, patients will have access to clean and affordable medicine, and university research partners will help the company expand the frontiers of medical marijuana in the years ahead. To learn more about MediJean and their plan to lead this new industry visit www.medijean.com and signup for their regular updates.
For further information:
For more information about MediJean please contact: